(Total Views: 244)
Posted On: 01/07/2019 5:26:22 PM
Post# of 72444
nice to see ..
News News Alert: Current Report Filing (8-k) 01/07/2019 04:32:21 PM
italics below are mine
===================
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 31, 2018, Mark R. Tobin resigned from his position as a director of Innovation Pharmaceuticals Inc. (the “Company”), effective immediately. Given the increased demands of his full-time job, Mr. Tobin does not have the time necessary to devote to the Company to fill the position of director. His resignation was not a result of any disagreement with the Company.
On January 7, 2019, Arthur P. Bertolino, MD, PhD, MBA, the Company’s President and Chief Medical Officer, joined the Board of Directors. The Company is currently exploring options for further Board additions in preparation for late-stage clinical trials and ongoing portfolio development.
There are no related party transactions between the Company and Dr. Bertolino that would require disclosure under Item 404(a) of Regulation S-K. A description of Dr. Bertolino’s compensation for his service as President and Chief Medical Officer of the Company is set forth under Item 11 of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on September 11, 2018. Dr. Bertolino will not receive any additional compensation for his service on the Board of Directors.
https://www.otcmarkets.com/filing/html?id=131...qOqQldC83h
4kids
News News Alert: Current Report Filing (8-k) 01/07/2019 04:32:21 PM
italics below are mine
===================
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 31, 2018, Mark R. Tobin resigned from his position as a director of Innovation Pharmaceuticals Inc. (the “Company”), effective immediately. Given the increased demands of his full-time job, Mr. Tobin does not have the time necessary to devote to the Company to fill the position of director. His resignation was not a result of any disagreement with the Company.
On January 7, 2019, Arthur P. Bertolino, MD, PhD, MBA, the Company’s President and Chief Medical Officer, joined the Board of Directors. The Company is currently exploring options for further Board additions in preparation for late-stage clinical trials and ongoing portfolio development.
There are no related party transactions between the Company and Dr. Bertolino that would require disclosure under Item 404(a) of Regulation S-K. A description of Dr. Bertolino’s compensation for his service as President and Chief Medical Officer of the Company is set forth under Item 11 of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on September 11, 2018. Dr. Bertolino will not receive any additional compensation for his service on the Board of Directors.
https://www.otcmarkets.com/filing/html?id=131...qOqQldC83h
4kids
Quote:
Dr B now on the Board of Directors per 8K. Those that were worried about his leaving the company can now rest assured he is here for the entire campaign.
(2)
(0)
